Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

How does one prevent potential cardiotoxic injury in oncological treatment? Shared risk factors with cardiovascular illnesses may complicate the treatment of cancer, and standard cardiology treatment procedures may have devastating side effects in oncology patients. Improved oncology treatments and the uncertain cardiovascular side effects of cancer therapies demand a sophisticated understanding of the new field of cardio-oncology. Wie lassen sich potentielle kardiotoxische Schäden in der onkologischen Behandlung vermeiden? Die verbesserte Diagnostik und Therapie onkologischer Erkrankungen führt auch zu neuen Herausforderungen in der Herz- und Kreislaufmedizin. Hierbei sind nicht nur die kurz- oder langfristigen Folgen onkologischer Therapieverfahren, z.B. die Entwicklung einer Herzinsuffizienz, gemeint, sondern auch kardiovaskuläre Folgen der onkologischen Grunderkrankung selbst wie Thrombosen oder Lungenembolien. Gemeinsame Risikofaktoren mit kardiovaskulären Erkrankungen können die Krebsbehandlung zunehmend erschweren. Umgekehrt können auch kardiologische Standardtherapieverfahren wie die Antikoagulation bei onkologischen Patienten verheerende Nebenwirkungen haben. Ein tumorfreies Überleben ist dementsprechend als alleiniges Therapieziel nicht ausreichend. Insbesondere verbesserte onkologische Therapien mit einem verlängerten Überleben von Risikopatienten sowie die rasche Einführung hochwirksamer onkologischer Therapieverfahren mit unklarem kardiovaskulärem Nebenwirkungsprofil erfordern profunde Kenntnisse auf dem neuen Gebiet der Kardio-Onkologie.

Cardiology. --- biomarkers. --- cardiac tumors. --- heart disease. --- heart failure. --- oncology. --- pericardial disease. --- stroke.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Diabetes --- Stem cells --- Heart failure --- Treatment. --- Transplantation. --- Cardiac failure --- Cardiac insufficiency --- Failure, Heart --- Insufficiency, Cardiac --- Heart --- Cardiac arrest --- Stem cell transplantation --- Cell transplantation --- Diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

It has been recognized that moderation in the use of salt (sodium chloride) prevents the tendency of blood pressure to increase with age. On the other hand, the abuse of salt frequently leads to increases in blood pressure and contributes to the development of hypertension, particularly in overweight or obese people, in people with diabetes, in the elderly, and in genetically predisposed subjects. This Special Issue aims to provide a better understanding of the relationship between sodium intake and related diseases, in particular: (i) the effect on health status and description of the biochemical processes involved; and (ii) the use of salt and related risks. The main topics are studies in the management and treatment of sodium-intake-related diseases, epidemiological studies of the relationship between salt intake and related diseases, focuses on the mechanism of action; delineation of the mechanisms of action, and in vitro and in vivo studies.

Research & information: general --- Biology, life sciences --- Food & society --- tight junction --- Na+ cotransport --- leaky epithelia --- blood pressure --- inflammation --- mineralocorticoid receptor --- Rac1 --- renal injury --- salt-sensitive hypertension --- salt intake --- sodium --- hypertension --- cardiovascular risk --- mortality --- prognosis --- salt --- heart failure --- ambulatory heart failure --- epidemiological studies --- MST3 --- STK24 --- high potassium --- ENaC --- NKCC2 --- SPAK --- OSR1 --- WNK4 --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Heart failure prevalence continues to rise globally. Regardless of the underlying etiology, heart failure remains a progressive disease, largely irreversible and end-stage heart failure requires transplantation. Book focuses on the challenges and recent advances of diagnosis, treatment and prevention of heart failure with or without associated comorbidities. We hope that readers will appreciate the wide breadth of topics and clinical utility of the articles and reviews included to this book collection.

Medicine --- Cardiovascular medicine --- biomarkers --- ST-segment elevation myocardial infarction --- preserved left ventricular ejection fraction --- reduced left ventricular ejection fraction --- heart failure --- NT-proBNP --- soluble ST2 --- galectin-3 --- matrix metalloproteinases --- tissue inhibitors of metalloproteinases --- mortality --- ejection fraction --- cardiopulmonary exercise test --- ventilatory inefficiency --- angiotensin receptor–neprilysin inhibitor --- echocardiography --- HFrEF --- risk stratification --- left ventricle end-diastolic diameter --- E/e’ ratio --- left ventricle outflow tract velocity-time integral --- hospitalization predictor --- short-term prognosis --- heart failure readmission --- acute myocardial infarction --- blood biomarkers --- diagnosis --- congestion --- clinical assessment --- preserved ejection fraction --- type 2 diabetes mellitus --- myocardial infarction --- chronic heart failure --- heart rate variability --- 2D echocardiography --- 24-h ECG monitoring --- chronic kidney disease --- pulmonary hypertension --- arteriovenous fistulas --- overhydration --- heart transplant --- cardiac allograft vasculopathy --- heart transplant rejection --- transthoracic echocardiography --- longitudinal strain --- sensing parameters --- pacing parameters --- adverse left ventricular remodeling --- left ventricular-arterial coupling --- fatty liver --- cardiovascular disease --- fibrosis --- epicardial fat --- left atrial strain --- edema --- dilated cardiomyopathy --- fluid management --- endothelial dysfunction --- n/a --- angiotensin receptor-neprilysin inhibitor --- E/e' ratio

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Heart failure prevalence continues to rise globally. Regardless of the underlying etiology, heart failure remains a progressive disease, largely irreversible and end-stage heart failure requires transplantation. Book focuses on the challenges and recent advances of diagnosis, treatment and prevention of heart failure with or without associated comorbidities. We hope that readers will appreciate the wide breadth of topics and clinical utility of the articles and reviews included to this book collection.

biomarkers --- ST-segment elevation myocardial infarction --- preserved left ventricular ejection fraction --- reduced left ventricular ejection fraction --- heart failure --- NT-proBNP --- soluble ST2 --- galectin-3 --- matrix metalloproteinases --- tissue inhibitors of metalloproteinases --- mortality --- ejection fraction --- cardiopulmonary exercise test --- ventilatory inefficiency --- angiotensin receptor–neprilysin inhibitor --- echocardiography --- HFrEF --- risk stratification --- left ventricle end-diastolic diameter --- E/e’ ratio --- left ventricle outflow tract velocity-time integral --- hospitalization predictor --- short-term prognosis --- heart failure readmission --- acute myocardial infarction --- blood biomarkers --- diagnosis --- congestion --- clinical assessment --- preserved ejection fraction --- type 2 diabetes mellitus --- myocardial infarction --- chronic heart failure --- heart rate variability --- 2D echocardiography --- 24-h ECG monitoring --- chronic kidney disease --- pulmonary hypertension --- arteriovenous fistulas --- overhydration --- heart transplant --- cardiac allograft vasculopathy --- heart transplant rejection --- transthoracic echocardiography --- longitudinal strain --- sensing parameters --- pacing parameters --- adverse left ventricular remodeling --- left ventricular-arterial coupling --- fatty liver --- cardiovascular disease --- fibrosis --- epicardial fat --- left atrial strain --- edema --- dilated cardiomyopathy --- fluid management --- endothelial dysfunction --- n/a --- angiotensin receptor-neprilysin inhibitor --- E/e' ratio